Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019047899) UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T-CELL PREPARATION TECHNIQUE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/047899 International Application No.: PCT/CN2018/104418
Publication Date: 14.03.2019 International Filing Date: 06.09.2018
IPC:
C12N 5/10 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10
Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Applicants:
亘喜生物科技(上海)有限公司 GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. [CN/CN]; 中国上海市 徐汇区宜山路926号1幢12层 12th Floor, Building 1, 926 Yishan Road Xuhui District Shanghai 200233, CN
Inventors:
施中东 SHI, Zhongdong; CN
刘丽萍 LIU, Liping; CN
杨春晖 YANG, Chunhui; CN
孙静 SUN, Jing; CN
蔡松柏 CAI, Songbai; CN
曹卫 CAO, Wei; CN
Agent:
上海一平知识产权代理有限公司 XU & PARTNERS, LLC.; 中国上海市 普陀区真北路958号天地科技广场1号楼106室 Room 106, Building No. 1, Universal High-Tech Plaza, 958 Zhen Bei Road, Putuo District Shanghai 200333, CN
Priority Data:
201710797952.406.09.2017CN
Title (EN) UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T-CELL PREPARATION TECHNIQUE
(FR) TECHNIQUE DE PRÉPARATION DE LYMPHOCYTES T UNIVERSELS À RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE
(ZH) 通用型嵌合抗原受体T细胞制备技术
Abstract:
(EN) Provided are a universal chimeric antigen receptor (CAR) T-cell and preparation method and application thereof. The binding of the cell HLA-A/HLA-B to the TCR is inhibited; the TCR gene expression is silenced; the invention may be used for allogeneic tumor treatment and does not cause GVHD and HVG reaction during allogeneic infusion, and thus improves the survival and antineoplastic effect of allogeneic CAR T-cells in the receptor.
(FR) L'invention porte sur un lymphocyte T universel à récepteur antigénique chimérique (CAR) et un procédé de préparation et une application associés. La liaison de la cellule HLA-A/HLA-B au TCR est inhibée ; l'expression du gène TCR est réduite au silence ; l'invention peut être utilisée pour le traitement de tumeur allogénique et ne provoque pas de réaction de GVHD et de HVG pendant une perfusion allogénique et améliore ainsi la survie et l'effet antinéoplasique de lymphocytes T CAR allogéniques chez le receveur.
(ZH) 提供了一种通用型嵌合抗原受体CAR-T细胞及其制备方法和应用。所述细胞HLA-A/HLA-B与TCR的结合被抑制,TCR基因表达被沉默,可以用于异体肿瘤治疗,且异体输注时不会引起GVHD及HVG反应,改善了异体CAR-T细胞在受体体内的存活及抗肿瘤效果。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)